Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: long-term oncologic outcomes.
Sang Woo ParkJin Soo KimJi Yeon KimKyung-Ha LeePublished in: Annals of surgical treatment and research (2018)
Additional 4-week chemotherapy with capecitabine, during the resting periods following a 6-week NCRT regimen, has favorable long-term oncologic outcomes. Further randomized controlled trials are however necessary to evaluate if substantial improvement in local control is achieved with this additional chemotherapy modality for locally advanced rectal cancer.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- phase ii study
- heart rate
- randomized controlled trial
- placebo controlled
- heart rate variability
- squamous cell carcinoma
- radiation therapy
- type diabetes
- metabolic syndrome
- adipose tissue
- double blind
- glycemic control
- insulin resistance
- study protocol
- skeletal muscle